Status:
TERMINATED
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)
Lead Sponsor:
Corcept Therapeutics
Conditions:
Nonalcoholic Steatohepatitis (NASH)
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH).
Detailed Description
This is a randomized, double-blind, placebo-controlled study that assessed the safety efficacy and pharmacokinetics (PK) of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH). ...
Eligibility Criteria
Inclusion
- Have a diagnosis of NASH based on a biopsy obtained within the last year OR
- Have a diagnosis of presumed NASH based on blood tests and scans
Exclusion
- Have participated in another clinical trial within the last year and received active treatment for NASH
- Have participated in another clinical trial for any other indication within the last 3 months
- Are pregnant or lactating women
- Have a BMI \<18 kg/m\^2
- Have had liver transplantation or plan to have liver transplantation during the study
- Have type 1 diabetes or poorly controlled type 2 diabetes.
Key Trial Info
Start Date :
November 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 5 2021
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03823703
Start Date
November 4 2020
End Date
April 5 2021
Last Update
August 31 2022
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 207
Chandler, Arizona, United States, 85224
2
Site 208
Glendale, Arizona, United States, 85306
3
Site 209
Tucson, Arizona, United States, 85712
4
Site 227
Los Angeles, California, United States, 90057